Eureka Therapeutics and Memorial Sloan Kettering (MSK) have built a new model of CAR-T cells, ones with powerful “armor” that allow them to fight solid tumors. A paper describing the approach was published in the journal Nature Biotechnology. The new cells combine two of the most promising types of immunotherapy – chimeric antigen receptor (CAR) T cells and checkpoint inhibitors – into one package. By engineering checkpoint inhibitors directly into the CAR-T cell itsel...